Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Feb 22, 2011)
  • 8-K (Feb 15, 2011)
  • 8-K (Feb 1, 2011)
  • 8-K (Jan 20, 2011)
  • 8-K (Jan 18, 2011)
  • 8-K (Jan 12, 2011)

 
Other

Matrixx Initiatives 8-K 2010

Documents found in this filing:

  1. 8-K
  2. 8-K
e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) March 5, 2010
MATRIXX INITIATIVES, INC.
 
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE
 
(State or Other Jurisdiction of Incorporation)
     
001-31404   87-0482806
 
(Commission File Number)   (IRS Employer Identification No.)
     
8515 E. Anderson Drive, Scottsdale, Arizona   85255
 
(Address of Principal Executive Offices)   (Zip Code)
(602) 385-8888
 
(Registrant’s Telephone Number, Including Area Code)
NONE
 
(Former Name or Former Address, if Changed Since Last Report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 8.01 Other Events.
As previously reported, following months of informal discussions with the Food and Drug Administration (the “FDA”), on November 16, 2009, Matrixx Initiatives, Inc. (the “Company”) filed a response to the FDA’s June 16, 2009 warning letter regarding the Company’s nasal cold remedy products. In that response, the Company requested, among other things, that the FDA withdraw the warning letter. See the Company’s Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2009. On March 5, 2010, the FDA reaffirmed its original position and denied the Company’s request. The Company is currently evaluating its options.

2


 

SIGNATURES
     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  MATRIXX INITIATIVES, INC.
(Registrant)
 
 
  /s/ William J. Hemelt    
  William J. Hemelt   
  President and Chief Executive Officer   
 
Date: March 8, 2010

3

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki